Met Life Investment Management, LLC Replimune Group, Inc. Transaction History
Met Life Investment Management, LLC
- $14.7 Billion
- Q1 2024
A detailed history of Met Life Investment Management, LLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 26,645 shares of REPL stock, worth $223,018. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,645Holding current value
$223,018% of portfolio
0.0%Shares
28 transactions
Others Institutions Holding REPL
# of Institutions
154Shares Held
66.1MCall Options Held
79.4KPut Options Held
102K-
Baker Bros. Advisors LP New York, NY9.55MShares$79.9 Million0.99% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.55MShares$54.8 Million0.01% of portfolio
-
State Street Corp Boston, MA6.49MShares$54.3 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.87MShares$40.7 Million5.62% of portfolio
-
Black Rock Inc. New York, NY4.61MShares$38.6 Million0.0% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $413M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...